Combination immunotherapy shows promise for treating bladder cancer
Combination immunotherapy is producing response rates ranging from 26 to 38% among patients with metastatic bladder cancer in a clinical trial led by MD Anderson Cancer Center.
¡°Until the first, recent approval of immune checkpoint therapy, patients with bladder cancer have not had new treatment options for over 30 years. We¡¯re quickly moving from immune checkpoint monotherapy to immune checkpoint combination therapies to improve...
What we can learn from revolutionary melanoma treatment
The largest analysis of metastatic melanoma patients who received a targeted therapy combination shows the treatment provides long-term survival...
Molecular testing used to find the best clinical trial for triple negative breast cancer patients
A new trial underway at MD Anderson may lead to new therapies for triple negative breast cancer.
Fifteen to 20%?of breast cancers...
Predicting if cancer patients will develop highly fatal leukemia
Patients who¡¯ve been successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs).
A study conducted by researchers at?MD Anderson Cancer Center?revealed pre-leukemic mutations, called clonal hematopoiesis, may predict...
Most salons are complying with tanning bed ban ¡ª an important step in cancer prevention
When female employees of a mystery shopping firm called posing as 17-year-olds interested in tanning, 81% of indoor tanning facilities complied...
MD Anderson is bringing greater access to advanced cancer care in San Antonio
Â鶹ӳ» Health Science Center at San Antonio and Â鶹ӳ»?MD Anderson?Cancer Center are announcing...
Screening program helps save an uninsured man¡¯s life
Three years ago, Stephen Cadmus faced a dilemma. He needed?to see a doctor, but he had no health insurance.
To get the medical...